Trends of Antimalarial Resistance in Ethiopia and its Challenge on Malaria Control Program

Authors

  • Tekalign Deressa School of Biomedical and Laboratory Sciences, College of Medicine and Health Sciences, University of Gondar, Gondar, Ethiopia

DOI:

https://doi.org/10.37591/rrjom.v6i1.1521

Abstract

 

Antimalarial drugs resistance is one of the major obstacles for malaria control and curtails the life-span of several drugs. Resistance to well tolerated and effective antimalarial drugs such chloroquine and sulfadoxine-pyrimethamine (SP) has forced the switch of national policies to artemisinin-based combination therapy (ACT) for the treatment of falciparum malaria. The emergence of less sensitive clones of Plasmodium falciparum to the ACT drugs, shortly after its deployment, has posed a threat to the global malaria control programs. Thus, it is essential to monitor the efficacy of antimalarial drugs periodically for early detection of changing patterns of the parasites susceptibility profile. Ethiopia is one of the countries most affected by malaria; and thus, known for intensive deployment of antimalarials which is one of the drivers for the development of parasites resistance to antimalarial drugs. Although limited in number, recent reports indicate that there is an increasing trend of parasites resistance to the first-line antimalarial drugs. This review, therefore, aims to summarize the available literature on malaria drug resistance patterns in the country.

 

Keywords: Malaria, Plasmodium falciparum, Plasmodium vivax, antimalarial drug resistance, Chloroquine, Artemether-Lumefantrine

Cite this Article

Tekalign Deressa. Trends of antimalarial resistance in Ethiopia and its challenge on Malaria control program. Research & Reviews: Journal of Medicine.2016; 6(1): 38–44p.

Downloads

Published

2019-04-25

Issue

Vol. 6 No. 1 (2016)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.